Ranolazine
- Generic Name
- Ranolazine
- Brand Names
- Aspruzyo Sprinkle, Ranexa, Ranexa (previously Latixa)
- Drug Type
- Small Molecule
- Chemical Formula
- C24H33N3O4
- CAS Number
- 95635-55-5
- Unique Ingredient Identifier
- A6IEZ5M406
- Background
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drug...
- Indication
Ranolazine is indicated for the treatment of chronic angina. It can be used alone or in conjunction with nitrates, beta-blockers, angiotensin receptor blockers, anti-platelet drugs, calcium channel blockers, lipid-lowering drugs, and ACE inhibitors.
...
- Associated Conditions
- Chronic Angina, Ventricular Arrhythmia
- Associated Therapies
- -
Feasibility Trial for a Right Ventricular Failure Platform Trial
- Conditions
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 30
- Registration Number
- NCT06570473
A Study of Ranolazine in ALS
- Conditions
- Interventions
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Jeffrey Statland
- Target Recruit Count
- 72
- Registration Number
- NCT06527222
- Locations
- 🇺🇸
University of Kansas Medical Center, Fairway, Kansas, United States
Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 4
- Registration Number
- NCT04456517
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- OBS Pakistan
- Target Recruit Count
- 2000
- Registration Number
- NCT03486561
A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- TSH Biopharm Corporation Limited
- Target Recruit Count
- 20
- Registration Number
- NCT03401502
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Zhongzheng Dist, Taiwan
RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain
- Conditions
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2018-04-10
- Lead Sponsor
- Saint Thomas Health
- Registration Number
- NCT03257683
- Locations
- 🇺🇸
Saint Thomas Heart at Saint Thomas West, Nashville, Tennessee, United States
CiPA Phase 1 ECG Biomarker Validation Study
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Food and Drug Administration (FDA)
- Target Recruit Count
- 60
- Registration Number
- NCT03070470
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)
- First Posted Date
- 2017-02-07
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Amit Malhotra, MD
- Target Recruit Count
- 40
- Registration Number
- NCT03044964
- Locations
- 🇺🇸
Stern Cardiovascular Foundation, Inc, Southaven, Mississippi, United States
Targeting Right Ventricle in Pulmonary Hypertension Gilead
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 22
- Registration Number
- NCT02829034
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
A Study of Pharmacokinetics and Safety of Ranolazine PR in Healthy Korean and Caucasian Male Subjects
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- A.Menarini Asia-Pacific Holdings Pte Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT02817932
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.